Cited by 120Ophthalmology and Eye DisordersCancer Immunotherapy and BiomarkersDrug-Induced Ocular Toxicity

The DOI matches its Crossref record; 5 of the 6 references it cites were found in a registry or an index.

Drug-Induced Graves Disease From CTLA-4 Receptor Suppression

Borodic, Gary, Hinkle, David M., Cia, Yihong·2011·Ophthalmic Plastic & Reconstructive Surgery

Open this paper in CoChat — free account

Abstract

Monoclonal antibody, ipilimumab, useful for treatment of metastatic melanoma, blocks CTLA-4 mediated T-cell suppression and can also cause a Graves ophthalmopathy like syndrome. Epidemiologic study has linked variant polymorphisms of CTLA-4 receptor gene to the presence of thyroid eye disease. The combination of these observations suggests CTLA-4 mediated T-cell functions are important to the pathogenesis of thyroid-associated eye disease.

Integrity signals

Registry

Crossref · 10.1097/iop.0b013e3181ef72a1

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

T Cell Activation
Smith-Garvin, J. E., Koretzky, G. A., & Jordan, M. S. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132706 · Cited by 2,144
CTLA-4 gene polymorphism associated with Graves' disease in a Caucasian population
Yanagawa, T., Hidaka, Y., Guimarães, V. C., Soliman, M., & DeGroot, L. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.1.7829637 · Cited by 464
CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation.
Bashey, A., Medina, B., Corringham, S., Pasek, M., Carrier, E., Vrooman, L., Lowy, I., Solomon, S., Morris, L., Holland, H., et al. (2009) · Blood · doi:10.1182/blood-2008-07-168468 · Cited by 343
Immunoregulatory and Susceptibility Genes in Thyroid and Polyglandular Autoimmunity
Dittmar, M., & Kahaly, G. J. (2005) · Thyroid · doi:10.1089/thy.2005.15.239 · Cited by 66
Biologic Therapeutics in Thyroid-Associated Ophthalmopathy: Translating Disease Mechanism into Therapy
Naik, V. M., Khadavi, N. M., Naik, M. N., Hwang, C. J., Goldberg, R. A., Tsirbas, A., Smith, T. J., & Douglas, R. S. (2008) · Thyroid · doi:10.1089/thy.2007.0403 · Cited by 37

Show all 6 references

Sorted by citations

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,505
Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies.
Byun, D. J., Wolchok, J. D., Rosenberg, L. M., & Girotra, M. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.205 · Cited by 685
The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
Voskens, C., Goldinger, S. M., Loquai, C., Robert, C., Kaehler, K. C., Berking, C., Bergmann, T., Bockmeyer, C. L., Eigentler, T., Fluck, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053745 · Cited by 465
Endocrine toxicities of immune checkpoint inhibitors
Wright, J. J., Powers, A. C., & Johnson, D. B. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00484-3 · Cited by 441
Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
Corsello, S. M., Barnabei, A., Marchetti, P., De Vecchis, L., Salvatori, R., & Torino, F. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4075 · Cited by 403
CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects
Dalvin, L. A., Shields, C. L., Orloff, M., Sato, T., & Shields, J. A. (2018) · Retina · doi:10.1097/iae.0000000000002181 · Cited by 336
Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events
González-Rodríguez, E., Rodríguez‐Abreu, D., & on behalf of the Spanish Group for Cancer Immuno-Biotherapy (GETICA) (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0509 · Cited by 254
Immune-Related Thyroiditis with Immune Checkpoint Inhibitors
Iyer, P. C., Cabanillas, M. E., Waguespack, S. G., Hu, M. I., Thosani, S., Lavis, V. R., Busaidy, N. L., Subudhi, S. K., Diab, A., & Dadu, R. (2018) · Thyroid · doi:10.1089/thy.2018.0116 · Cited by 238
Immune-Mediated Adverse Events Associated with Ipilimumab CTLA-4 Blockade Therapy: The Underlying Mechanisms and Clinical Management
Tarhini, A. A. (2013) · Scientifica · doi:10.1155/2013/857519 · Cited by 239
Immune checkpoint inhibitor‐related hypophysitis and endocrine dysfunction: clinical review
Joshi, M., Whitelaw, B., Palomar, M. T. P., Wu, Y., & Carroll, P. (2016) · Clinical Endocrinology · doi:10.1111/cen.13063 · Cited by 224
Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma
Morganstein, D. L., Lai, Z., Spain, L., Diem, S., Levine, D., Mace, C., Gore, M., & Larkin, J. (2017) · Clinical Endocrinology · doi:10.1111/cen.13297 · Cited by 190
Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports
Tan, M. H., Iyengar, R., Mizokami-Stout, K., Yentz, S., MacEachern, M. P., Shen, L. Y., Redman, B., & Gianchandani, R. (2019) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-018-0073-4 · Cited by 172
Endocrine side effects of cancer immunotherapy
Cukier, P., Santini, F. C., Scaranti, M., & Hoff, A. O. (2017) · Endocrine-Related Cancer · doi:10.1530/erc-17-0358 · Cited by 177
Ocular Toxicity of Targeted Therapies
Renouf, D. J., Velazquez-Martin, J. P., Simpson, R., Siu, L. L., & Bedard, P. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.5851 · Cited by 139
Endocrinological side-effects of immune checkpoint inhibitors
Torino, F., Corsello, S. M., & Salvatori, R. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000293 · Cited by 138
Ocular and orbital side-effects of checkpoint inhibitors: a review article
Antoun, J., Titah, C., & Cochereau, I. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000296 · Cited by 139
Ipilimumab-induced Ocular and Orbital Inflammation—A Case Series and Review of the Literature
Papavasileiou, E., Prasad, S., Freitag, S. K., Sobrin, L., & Lobo, A. (2015) · Ocular Immunology and Inflammation · doi:10.3109/09273948.2014.1001858 · Cited by 128
The Current Understanding of the Endocrine Effects From Immune Checkpoint Inhibitors and Recommendations for Management
Girotra, M., Hansen, A. R., Farooki, A., Byun, D. J., Min, L., Creelan, B., Callahan, M. K., Atkins, M. B., Sharon, E., Antonia, S. J., et al. (2018) · JNCI Cancer Spectrum · doi:10.1093/jncics/pky021 · Cited by 131
Management of side effects of immune checkpoint blockade by anti‐CTLA‐4 and anti‐PD‐1 antibodies in metastatic melanoma
Kähler, K. C., Hassel, J. C., Heinzerling, L., Loquai, C., Mößner, R., Ugurel, S., Zimmer, L., & Gutzmer, R. (2016) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13047 · Cited by 120
Thyroid Dysfunction as an Unintended Side Effect of Anticancer Drugs
Torino, F., Barnabei, A., Paragliola, R., Baldelli, R., Appetecchia, M., & Corsello, S. M. (2013) · Thyroid® · doi:10.1089/thy.2013.0241 · Cited by 117
Thyroid disorders induced by checkpoint inhibitors
Ferrari, S. M., Fallahi, P., Galetta, F., Citi, E., Benvenga, S., & Antonelli, A. (2018) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-018-9463-2 · Cited by 113
Orbital Myositis: A Comprehensive Review and Reclassification
McNab, A. A. (2019) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000001429 · Cited by 100
Thyroid-Like Ophthalmopathy in a Euthyroid Patient Receiving Ipilimumab
McElnea, E., Ní Mhéalóid, Á., Moran, S., Kelly, R., & Fulcher, T. (2014) · Orbit · doi:10.3109/01676830.2014.949792 · Cited by 93
Time to dissect the autoimmune etiology of cancer antibody immunotherapy
Dougan, M. L., & Pietropaolo, M. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131194 · Cited by 92
Immune-mediated adverse events of anticytotoxic T lymphocyte–associated antigen 4 antibody therapy in metastatic melanoma
Quirk, S. K., Shure, A. K., & Agrawal, D. K. (2015) · Translational research · doi:10.1016/j.trsl.2015.06.005 · Cited by 82
Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study
Okada, N., Iwama, S., Okuji, T., Kobayashi, T., Yasuda, Y., Wada, E., Onoue, T., Goto, M., Sugiyama, M., Tsunekawa, T., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0736-7 · Cited by 78
Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders
Jannin, A., Penel, N., Ladsous, M., Vantyghem, M., & Cao, C. D. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.05.015 · Cited by 77
Extraocular Muscle Enlargement and Thyroid Eye Disease-like Orbital Inflammation Associated with Immune Checkpoint Inhibitor Therapy in Cancer Patients
Sagiv, O., Kandl, T. J., Thakar, S. D., Thuro, B. A., Busaidy, N. L., Cabanillas, M., Jimenez, C., Dadu, R., Graham, P. H., Debnam, J. M., et al. (2019) · Ophthalmic Plastic & Reconstructive Surgery · doi:10.1097/iop.0000000000001161 · Cited by 71
Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach
Iglesias, P. (2017) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2017.08.019 · Cited by 70
Graves’ Disease Induced by Immune Checkpoint Inhibitors: A Case Report and Review of the Literature
Brancatella, A., Viola, N., Brogioni, S., Montanelli, L., Sardella, C., Vitti, P., Marcocci, C., Lupi, I., & Latrofa, F. (2019) · European Thyroid Journal · doi:10.1159/000501824 · Cited by 69
Ocular adverse events associated with immune checkpoint inhibitors, a scoping review
Martens, A., Schauwvlieghe, P., Madoe, A., Casteels, I., & Aspeslagh, S. (2023) · Journal of Ophthalmic Inflammation and Infection · doi:10.1186/s12348-022-00321-2 · Cited by 68
Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review
Yu, C. W., Yau, M., Mezey, N., Joarder, I., & Micieli, J. A. (2020) · Eye and Brain · doi:10.2147/eb.s277760 · Cited by 62
Neoplasia and intraocular inflammation: From masquerade syndromes to immunotherapy-induced uveitis
Touhami, S., Audo, I. S., Terrada, C., Gaudric, A., LeHoang, P., Touitou, V., & Bodaghi, B. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.05.002 · Cited by 60
Current and future immunotherapies for thyroid cancer
Antonelli, A., Ferrari, S. M., & Fallahi, P. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1417845 · Cited by 59
A novel melanoma therapy stirs up a storm: ipilimumab-induced thyrotoxicosis
Yu, C. H., CHOPRA, I. J., & Ha, E. L. (2015) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-14-0092 · Cited by 49
Anticancer Drug-induced Thyroid Dysfunction
Bhattacharya, S., Goyal, A., Kaur, P., Medanta, T. M., Singh, R. K., & Kalra, S. (2020) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2020.16.1.32 · Cited by 50
Immunotherapy-induced endocrinopathies: assessment, management and monitoring
Nogueira, E. F., Newsom‐Davis, T., & Morganstein, D. L. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819896182 · Cited by 48
Ocular Inflammation Induced by Immune Checkpoint Inhibitors
Chaudot, F., Sève, P., Rousseau, A., Maria, A. T. J., Fournié, P., Lozac’h, P., Keraen, J., Servant, M., Muller, R., Gramont, B., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11174993 · Cited by 46
Multifocal bilateral choroidal neovascularization in a patient on ipilimumab for metastatic melanoma
Modjtahedi, B. S., Maïbach, H. I., & Park, S. (2013) · Cutaneous and Ocular Toxicology · doi:10.3109/15569527.2013.781618 · Cited by 46
American Association of Clinical Endocrinology Disease State Clinical Review: Evaluation and Management of Immune Checkpoint Inhibitor-Mediated Endocrinopathies: A Practical Case-Based Clinical Approach
Yuen, K. C. J., Samson, S. L., Bancos, I., Gosmanov, A. R., Jasim, S., Fecher, L. A., & Weber, J. S. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.04.010 · Cited by 46
Thyroid eye disease
Li, Z., Cestari, D. M., & Fortin, É. (2018) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000529 · Cited by 43
Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma
Wang, X., Zuo, D., Sarkar, D., & Fisher, P. B. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.629187 · Cited by 44
Severe Inflammatory Ophthalmopathy in a Euthyroid Patient during Nivolumab Treatment
Campredon, P., Imbert, P., Mouly, C., Grunenwald, S., Mazières, J., & Caron, P. J. (2018) · European Thyroid Journal · doi:10.1159/000485742 · Cited by 42
Thyroid Dysfunctions Due to Immune Checkpoint Inhibitors: A Review
Sabbagh, R. E., Azar, N. S., Eid, A. A., & Azar, S. T. (2020) · International Journal of General Medicine · doi:10.2147/ijgm.s261433 · Cited by 45
Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management
Zhou, Y., Wang, Y., Xia, R.-L., Liu, J., & Ma, X. (2022) · International Journal of Ophthalmology · doi:10.18240/ijo.2022.04.19 · Cited by 42
Inflammatory Orbitopathy Associated With Ipilimumab
Sheldon, C. A., Kharlip, J., & Tamhankar, M. A. (2015) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000000509 · Cited by 38
Steroid responsive encephalopathy associated with autoimmune thyroiditis following ipilimumab therapy: a case report
Carl, D. J., Grüllich, C., Hering, S., & Schabet, M. (2015) · BMC Research Notes · doi:10.1186/s13104-015-1283-9 · Cited by 36
New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient
Miserocchi, E., Cimminiello, C., Mazzola, M., Russo, V. E. A., & Modorati, G. M. (2015) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2014.10.010 · Cited by 35
Ophthalmic complications of targeted cancer therapy and recently recognized ophthalmic complications of traditional chemotherapy
Kheir, W. J., Sniegowski, M. C., El-Sawy, T., Li, A. L., & Esmaeli, B. (2014) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2014.02.004 · Cited by 36
Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries
Vouk, K., Benter, U., Amonkar, M. M., Marocco, A., Stapelkamp, C., Pfersch, S., & Benjamin, L. (2016) · Journal of Medical Economics · doi:10.1080/13696998.2016.1184155 · Cited by 33
A Case Report of Orbital Inflammatory Syndrome Secondary to Ipilimumab
Henderson, A. D., & Thomas, D. A. (2014) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000000081 · Cited by 34
Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review)
Peiffert, M., Cugnet-Anceau, C., Dalle, S., Chikh, K., Assaad, S., Disse, E., Raverot, G., Borson-Chazot, F., & Abeillon-du Payrat, J. (2021) · Cancers · doi:10.3390/cancers13081944 · Cited by 33
Ocular side effects of biological agents in oncology: what should the clinician be aware of?
Hager, T., & Seitz, B. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s54606 · Cited by 33
Approach to the Patient With Immune Checkpoint Inhibitor–Associated Endocrine Dysfunction
Wright, J. J., & Johnson, D. B. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac689 · Cited by 31
Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events
Hoefsmit, E. P., Rozeman, E. A., Haanen, J. B. A. G., & Blank, C. U. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000472 · Cited by 29
Immune checkpoints: new insights into the pathogenesis of thyroid eye disease
Shu, X., Shao, Y., Chen, Y., Zeng, C., Huang, X., & Wei, R.-L. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1392956 · Cited by 30
Ocular side effects of checkpoint inhibitors
Alba‐Linero, C., & Alba, E. (2021) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2021.01.001 · Cited by 29
Diagnostic criteria and proposed management of immune-related endocrinopathies following immune checkpoint inhibitor therapy for cancer
Percik, R., Criseno, S., Adam, S., Young, K., & Morganstein, D. L. (2023) · Endocrine Connections · doi:10.1530/ec-22-0513 · Cited by 28
Nebenwirkungsmanagement bei Immun‐Checkpoint‐Blockade durch CTLA‐4‐ und PD‐1‐Antikörper beim metastasierten Melanom – ein Update
Kähler, K. C., Hassel, J. C., Heinzerling, L., Loquai, C., Thoms, K., Ugurel, S., Zimmer, L., Gutzmer, R., & (ADO), F. D. K. „. N. D. A. D. O. (2020) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14128_g · Cited by 27
Emerging Ocular Side Effects of Immune Checkpoint Inhibitors: A Comprehensive Review
Wu, K. Y., Yakobi, Y., Gueorguieva, D. D., & Mazerolle, É. (2024) · Biomedicines · doi:10.3390/biomedicines12112547 · Cited by 28
Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer
Rossi, E., Sgambato, A., Chiara, G. D., Casaluce, F., Losanno, T., Sacco, P. C., Santabarbara, G., & Gridelli, C. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1133289 · Cited by 26
Endocrine toxicity of cancer immunotherapy: clinical challenges
Anderson, B., & Morganstein, D. L. (2021) · Endocrine Connections · doi:10.1530/ec-20-0489 · Cited by 26
Disturbances of Modulating Molecules (FOXP3, CTLA‐4/CD28/B7, and CD40/CD40L) mRNA Expressions in the Orbital Tissue from Patients with Severe Graves’ Ophthalmopathy
Pawłowski, P., Wawrusiewicz-Kurylonek, N., Eckstein, A. K., Reszeć, J., Łuczyński, W., Johnson, K. T. M., Kretowski, A. J., Bakunowicz‐Łazarczyk, A., Górska, M., Szamatowicz, J., et al. (2015) · Mediators of Inflammation · doi:10.1155/2015/340934 · Cited by 26
Immune checkpoint inhibitors and endocrine side effects, a narrative review
Agrawal, L., Bacal, A., Jain, S., Singh, V., Emanuele, N. V., Emanuele, M. A., & Meah, F. A. (2019) · Postgraduate Medicine · doi:10.1080/00325481.2019.1709344 · Cited by 26
A case of Graves' ophthalmopathy associated with pembrolizumab (Keytruda) therapy
Park, E. S., Rabinowits, G., Hamnvik, O. R., & Dagi, L. R. (2018) · Journal of American Association for Pediatric Ophthalmology and Strabismus · doi:10.1016/j.jaapos.2018.01.006 · Cited by 22
Ipilimumab-Induced Orbital Inflammation Resembling Graves Disease With Subsequent Development of Systemic Hyperthyroidism From CTLA-4 Receptor Suppression
Borodic, G. E., & Hinkle, D. M. (2014) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000000033 · Cited by 20
Nivolumab-induced thyroid dysfunction in patients with lung cancer
Ramos-Levi, A. M., Rogado, J., Sánchez-Torres, J. M., Colomer, R., & Marazuela, M. (2018) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2018.05.005 · Cited by 20
Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma
Alnabulsi, R., Hussain, A., & DeAngelis, D. (2018) · Orbit · doi:10.1080/01676830.2017.1423349 · Cited by 19
Implications of FoxP3-positive and -negative CD4+ CD25+ T cells in Graves’ ophthalmopathy
Matsuzawa, K., Izawa, S., Okura, T., Fujii, S., Matsumoto, K., Shoji, K., Nakamura, R., Sumi, K., Fujioka, Y., Yoshida, A., et al. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej16-0108 · Cited by 19
The side effects of immune checkpoint inhibitor therapy on the endocrine system
Goyal, I., Pandey, M. R., Sharma, R. K., Chaudhuri, A., & Dandona, P. (2021) · International Journal of Microbiology Research · doi:10.4103/ijmr.ijmr_313_19 · Cited by 18
Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not)
Corsello, S. M., Salvatori, R., Barnabei, A., Vecchis, L. D., Marchetti, P., & Torino, F. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2213-y · Cited by 17
Thyroid-Induced Toxicity of Check-Point Inhibitors Immunotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer
Gridelli, C. (2016) · Journal of Endocrinology and Diabetes · doi:10.15226/2374-6890/3/1/00143 · Cited by 15
Cancer Therapy with Checkpoint Inhibitors: Establishing a Role for Ophthalmology
Davis, M. E., & Francis, J. H. (2017) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2017.08.003 · Cited by 15
Ocular side effects of target therapy and immunotherapy in patients with cutaneous malignant melanoma
Eikenberry, J. L., Harris, A., Torabi, R., Lang, M., Denney, D., Vercellin, A. C. V., & Siesky, B. A. (2020) · European Journal of Ophthalmology · doi:10.1177/1120672120930688 · Cited by 15
The Diagnosis and Management of Endocrine Side Effects of Immune Checkpoint Inhibitors
Mai, K., Faßnacht, M., Führer‐Sakel, D., Honegger, J. B., Weber, M. M., & Kroiß, M. (2021) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2021.0143 · Cited by 15
Re
Sohrab, M. A., Desai, R. U., Chambers, C. B., & Lissner, G. S. (2013) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0b013e3182895795 · Cited by 14
Immunological Processes in the Orbit and Indications for Current and Potential Drug Targets
Cieplińska, K., Niedziela, E., & Kowalska, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010072 · Cited by 13
Metastatic melanoma: Pathologic characterization, current treatment, and complications of therapy
Wick, M. R., & Gru, A. A. (2016) · Seminars in Diagnostic Pathology · doi:10.1053/j.semdp.2016.04.005 · Cited by 13
Ipilimumab-related orbitopathy: a case report
Jebaraj, A. P., Etheridge, T. J., Winegar, B. A., & Marx, D. P. (2022) · Orbit · doi:10.1080/01676830.2022.2074049 · Cited by 11
Nebenwirkungsmanagement bei Immun‐Checkpoint‐Blockade durch CTLA‐4‐ und PD1‐Antikörper beim metastasierten Melanom
Kähler, K. C., Hassel, J. C., Heinzerling, L., Loquai, C., Mößner, R., Ugurel, S., Zimmer, L., Gutzmer, R., & (ADO), F. D. K. „. N. D. A. D. O. (2016) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.13047_g · Cited by 11
Molecularly targeted agents in oculoplastic surgery
Allen, R. C. (2017) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000403 · Cited by 11
Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma
Nardin, C., Borot, S., Beaudoin, M. A., Cattin, F., Puzenat, E., Gauthier, A.-S., Schillo, F., Borg, C., & Aubin, F. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0659-9 · Cited by 10
Neuro-ophthalmic Complications of Immune-Checkpoint Inhibitors
Mukharesh, L., & Chwalisz, B. K. (2021) · Seminars in Ophthalmology · doi:10.1080/08820538.2021.1890796 · Cited by 10
Immune checkpoint inhibitors
Douglas, V. P., Douglas, K. A. A., & Cestari, D. M. (2019) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000608 · Cited by 9
Considerations for Use of Immune Checkpoint Inhibitors in Cancer Therapy for Patients with Co-Existing Thyroid Eye Disease
Chau, C. Y. C., Shih, K. C., Chow, L. L. W., & Lee, V. H.-F. (2020) · Ophthalmology and Therapy · doi:10.1007/s40123-020-00317-y · Cited by 9
Effets indésirables oculaires des traitements systémiques : une mise à jour
Rousseau, A., & Labétoulle, M. (2015) · Journal Français d Ophtalmologie · doi:10.1016/j.jfo.2015.05.004 · Cited by 7
Reply re
Borodic, G. E., & Hinkle, D. M. (2013) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0b013e31828957c3 · Cited by 7
Case Report: Development of severe inflammatory orbitopathy after immune checkpoint inhibitor initiation
Madala, S., Parikh, A. O., Hong, K., & Burnstine, M. A. (2025) · Frontiers in Ophthalmology · doi:10.3389/fopht.2025.1574643 · Cited by 5
Checkpoint inhibitor-related myasthenia-myocarditis-myositis overlap syndrome in the orbit
Park, B. J., Warning, A. W., & Akella, S. S. (2024) · Orbit · doi:10.1080/01676830.2024.2351519 · Cited by 5
Pathogenesis of Thyroid Eye Disease
Spadaro, J. Z., & Kohli, A. A. (2023) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000464 · Cited by 5
Immune checkpoint inhibitors associated thyroiditis: mechanisms and clinical outcomes
Hammerstad, S. S., Lee, H. J., Tomer, Y., & Stefan–Lifshitz, M. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02608-2 · Cited by 4
Real-World Evaluation of Immune-Related Endocrinopathies in Metastatic NSCLC Patients Treated with ICIs in Romania
Coniac, S., Costache-Outas, M. C., Antone-Iordache, I.-L., Barbu, A.-M., Bardan, V. T., Zamfir, A., Ionescu, A.-I., & Badiu, C. (2025) · Cancers · doi:10.3390/cancers17071198 · Cited by 4
Lenalidomide-Associated Thyroid-Related Eyelid Retraction
Slean, G. R., & Silkiss, R. Z. (2017) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000001012 · Cited by 4
R-CHOP-Associated Graves’ Hyperthyroidism
Mora, N., Vu, K., Hoang, T. D., Mai, V. Q., & Shakir, M. K. M. (2019) · Case Reports in Oncology · doi:10.1159/000501714 · Cited by 4
Thyroid Function Abnormalities in Patients Receiving Anticancer Agents
Torino, F., Barnabei, A., Baldelli, R., & Appetecchi, M. (2012) · InTech eBooks · doi:10.5772/50375 · Cited by 4
New-Onset Graves’ Ophthalmopathy After Treatment with Pembrolizumab: A Case Report and a Review of the Literature
Pan, M., Zhou, X., & Wu, Y. F. (2025) · Diagnostics · doi:10.3390/diagnostics15212764 · Cited by 3
Targeted Therapy and Their Ocular Complications
Jusufbegovic, D., Triozzi, P. L., & Singh, A. D. (2013) · Springer eBooks · doi:10.1007/978-3-642-40489-4_13 · Cited by 3
Nivolumab-induced thyroid dysfunction in patients with lung cancer
Ramos-Levi, A. M., Rogado, J., Sánchez-Torres, J. M., Colomer, R., & Marazuela, M. (2019) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2018.12.001 · Cited by 4
Iatrogenic affectation of ocular motility by immune checkpoint inhibitors
Jiménez-Ortiz, H. F., Rodríguez, B. M., Monjas, R. L., Yáñez, R. S., Santos, I. S., & Fernández, N. T. (2023) · Archivos de la Sociedad Española de Oftalmología (English Edition) · doi:10.1016/j.oftale.2023.11.011 · Cited by 2
Immune Checkpoints and Graves’ Disease, Thyroid Eye Disease, and Orbital Myopathy: A Comprehensive Review
Souri, Z., & Pakdel, F. (2024) · Journal of Ophthalmic and Vision Research · doi:10.18502/jovr.v19i3.15047 · Cited by 2

Authors: Borodic, G., Hinkle, D. M., & Cia, Y.
Affiliations: Massachusetts Eye and Ear Infirmary (US)
Harvard University (US)
Corresponding author: Borodic, Gary
ORCID: Hinkle, David M.
Venue: Ophthalmic Plastic & Reconstructive Surgery
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2011-07
Volume: 27
Issue: 4
Pages: e87-e88
ISSN: 0740-9303 (ISSN-L)
DOI: 10.1097/iop.0b013e3181ef72a1
OpenAlex: W1988822265
Cited by: 120
References: 6
Citations by year: 2026: 4 · 2025: 5 · 2024: 7 · 2023: 6 · 2022: 7 · 2021: 9 · 2020: 9 · 2019: 13 · 2018: 13 · 2017: 7 · 2016: 13 · 2015: 10 · 2014: 4 · 2013: 10 · 2012: 2
FWCI: 3.81
Type: journal article
Language: en
Open access: closed
Locations: Ophthalmic Plastic and Reconstructive Surgery (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Ophthalmology › Ophthalmology and Eye Disorders
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Ophthalmology › Drug-Induced Ocular Toxicity
Keywords: ipilimumab, CTLA-4 blockade, Graves' ophthalmopathy, T cell suppression, metastatic melanoma, CTLA-4 gene polymorphism, autoimmune thyroid disease
MeSH terms: Ipilimumab, Antibodies, Monoclonal, Antineoplastic Agents, Diplopia, Exophthalmos, Female, Humans, Lung Neoplasms, Magnetic Resonance Imaging, Melanoma, Middle Aged, Neoplasms, Unknown Primary, Oculomotor Muscles, Antigens, CD, Graves Ophthalmopathy, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Drug-Induced Graves Disease From CTLA-4 Receptor Suppression

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks